News|Articles|November 17, 2026

Zipalertinib/Chemo NDA Submission Completed in Frontline EGFR Exon 20 NSCLC

Fact checked by: Ariana Pelosci

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

A new drug application (NDA) submission has been completed and submitted to the FDA for zipalertinib (CLN-081/TAS6417) in combination with platinum-based chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to a news release from Cullinan Therapeutics.1

The submission was made under the FDA’s Real-Time Oncology Review (RTOR) program, which allows sponsors to submit clinical data before the full application is complete. The application will proceed through the standard review period, and if the FDA accepts it, the agency will assign a Prescription Drug User Fee Act (PDUFA) target action date. The rolling submission was initiated in early October 2026, at which time it was expected to be completed by the end of the year.2

The NDA is supported by findings from the phase 3 REZILIENT3 trial (NCT05973773), which met its primary end point at a prespecified interim analysis, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with zipalertinib plus chemotherapy vs chemotherapy alone. Results were presented during a Presidential Symposium at the 2026 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).1,3

As of a data cutoff of May 29, 2026, the median PFS by blinded independent central review (BICR) was 14.5 months (95% CI, 12.9-21.4) with zipalertinib plus chemotherapy compared with 8.5 months (95% CI, 7.0-10.9) with chemotherapy alone (HR, 0.50; 95% CI, 0.34-0.73; P = .00015). The PFS benefit was consistent across prespecified subgroups. According to the developer, this represents the longest median PFS observed to date in the first-line setting for patients with NSCLC harboring EGFR exon 20 insertion mutations.2,3

The objective response rate (ORR) was 65.0% (95% CI, 56.49%-72.86%) in the combination arm vs 40.3% (95% CI, 32.06%-48.94%) in the chemotherapy-alone arm (P <.0001), and the disease control rate was 89.3% (95% CI, 82.94%-93.88%) vs 81.3% (95% CI, 73.81%-87.40%), respectively. The median duration of response (DOR) was 14.2 months (95% CI, 10.51-not evaluable [NE]) with the combination compared with 9.9 months (95% CI, 6.80-NE) with chemotherapy alone.2,3

Regarding safety, treatment-related adverse events (TRAEs) occurred in 98.6% of patients in the zipalertinib arm and 88.2% of those in the control arm, with grade 3 or higher TRAEs reported in 80.7% and 40.4%, respectively. Serious adverse events occurred in 50.7% vs 33.1% of patients. Adverse events led to death in 9.3% of patients who received the combination and 2.9% of those who received chemotherapy alone; treatment-related deaths occurred in 2.1% of the combination arm, all of which were due to sepsis or septic shock.2,3

Investigators reported that most grade 3 or higher events were attributable to cytopenias, which occurred primarily during the first 4 treatment cycles. These events were managed through patient selection, dose modifications, and supportive care.2

The randomized, global phase 3 REZILIENT3 trial enrolled 280 patients with previously untreated, locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations across 122 sites. Eligible patients had an ECOG performance status of 0 or 1, and those with stable brain metastases were permitted to enroll. Following a safety lead-in, patients were randomly assigned to receive zipalertinib at 100 mg twice daily plus pemetrexed and platinum chemotherapy (carboplatin or cisplatin), or pemetrexed and platinum chemotherapy alone. Crossover was optional.

The trial’s primary end point was PFS by BICR. Secondary end points included overall survival, investigator-assessed PFS, ORR, DOR, safety, and patient-reported outcomes.

Zipalertinib is an investigational, orally available, next-generation irreversible EGFR inhibitor designed to target EGFR variants with exon 20 insertion mutations. The agent is being developed in the US by Taiho Oncology, its parent company Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics. It has not been approved by any health authority for any use.1

The FDA previously granted breakthrough therapy designation to zipalertinib for patients with EGFR exon 20 insertion–positive NSCLC who previously received platinum-based chemotherapy. A separate NDA seeking accelerated approval for zipalertinib monotherapy in that previously treated population is currently under review, with a PDUFA target action date of February 27, 2027.2

References

  1. Cullinan Therapeutics announces new drug application submission completed for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung cancer. News release. Cullinan Therapeutics. November 12, 2026. Accessed November 16, 2026. https://tinyurl.com/2wfxet4c
  2. New drug application submission initiated for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC for review under FDA Real-Time Oncology Review program. News release. Cullinan Therapeutics Inc. October 1, 2026. Accessed November 16, 2026. https://tinyurl.com/3hryejjd
  3. Tan DSW, Danchaivijitr P, Shinno Y, et al. Zipalertinib plus chemotherapy for 1st line mNSCLC with EGFR exon 20 insertions: results from the phase 3 trial (REZILIENT 3). Abstract presented at: International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract PL03.04

Related to this article